neovasc
Invendo Medical raised $28 million for its single-use colonoscopy system | Medtech funding stories for the week of Mar. 24, 2014
Neovasc raises $22.5M for cardiac implants
Neovasc soars on 1st-in-human implant of Tiara transcatheter mitral valve
Cleveland HeartLab pulls in $15M | Wall Street Beat
Cleveland HeartLab pulled in $14.7 million in equity financing for its proprietary test for cardiac inflammation, according to a regulatory filing.
The CardioMPO test was developed by Dr. Stanley Hazen, director of the Cleveland Clinic’s center for cardiovascular diagnostics and prevention.
Cleveland HeartLab closed a $3 million round in 2010, with backers including Glengary and Second Generation Ltd.
LeMaitre Vascular pays $5M for Neovasc’s XenoSure | Wall Street Beat
LeMaitre Vascular (NSDQ:LMAT) said it will pay $4.6 million for Neovasc‘s (NYSE:NVC) XenoSure vascular patch, used to repair blood vessels.
St. Jude Medical wins CE Mark, launches Enlightn renal denervation system | MassDevice.com On Call
MASSDEVICE ON CALL —St. Jude Medical (NYSE:STJ) landed CE Mark approval and announced commercial launch for its Enlightn renal denervation system as a treatment for hypertension.
Zimmer slides on Q1 results | Earnings Roundup
Diabetes: Medtronic wins clearance for next-gen clinical continuous glucose monitor | Regulatory Roundup
Medtronic Inc. (NYSE:MDT) won FDA clearance for its next generation iPro2 Professional continuous glucose monitor.
The iPro2 Professional is a clinician-owned device that collects glucose data from a sensor inserted into a patient’s skin.
The device tracks the patient’s glucose levels for 3 days, collecting data as many as 288 times each day. The information may provide insight into how diet, medication and daily activities affect a patient’s glucose levels.